Drugmakers probed in Italy over possible agreement over eye treatment ranibizumab
MLex Summary: Several drugmakers — including Samsung Bioepis, Novartis and Biogen — are being probed by the Italian antitrust authority over a possible coordination of commercial strategies to delay the entry...To view the full article, register now.
Already a subscriber? Click here to view full article